<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article227</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/APEX" style="display:block; margin-bottom:10px;">APEX Original</a></li>
<h2><strong>APEX</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "BRIXABAN for Acute Medical Illness". The New England Journal of Medicine. 2016.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does extended-duration thromboprophylaxis with betrixaban reduce the risk of venous thromboembolism compared to standard-duration enoxaparin in acutely ill medical patients?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Extended-duration thromboprophylaxis with betrixaban did not significantly reduce the risk of venous thromboembolism in acutely ill medical patients compared to standard-duration enoxaparin in the prespecified primary efficacy cohort. Exploratory analyses suggest a possible benefit in larger patient cohorts.<br/>
<br/>
<h2><strong>Major Points </strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
No clear guidelines were established based on this study for the extension of thromboprophylaxis after hospital discharge.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, parallel-group, randomized, controlled trial comparing extended-duration betrixaban with standard-duration enoxaparin<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
7,513 patients hospitalized with acute medical illnesses, reduced mobility, and additional risk factors for venous thromboembolism.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Betrixaban for 35 to 42 days versus subcutaneous enoxaparin for 10Â±4 days<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Efficacy Outcome: Composite of asymptomatic proximal deep-vein thrombosis (DVT), symptomatic venous thromboembolism, between days 1 to 42.<br/>
Primary Safety Outcome: Major bleeding up to 7 days after discontinuation of study medication.<br/>
Secondary Efficacy Outcomes: Symptomatic venous thromboembolism and composite of asymptomatic proximal DVT, symptomatic DVT, nonfatal pulmonary embolism, or death from any cause through day 42.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
Approximately 15% of enrolled patients did not undergo adequate ultrasonography, thus could not be included in the main analyses of the efficacy outcomes.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Portola Pharmaceuticals<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. The New England Journal of Medicine. 2016.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
